Biotech vets pick up $10M B round for startup Alcresta

Ryan McBride Alcresta has fueled up with venture dollars en route to commercialization of its biotech-inspired nutritional products with a $ 10 million Series A round from previous ...

$1.3B VC cash surge buoys biotech as analysts point to a rebound

John Carroll FierceBiotech News

OncoMed extends the biotech IPO winning streak with $82M haul

John Carroll The company not only finally managed to make the IPO leap, it joined a select few which have priced their shares above the range, boosting their take and proving once again ...

Biotech inspires jump in healthcare VC activity in Q2

Ryan McBride As biotech deals sizzle, venture investors took more gambles on healthcare ventures in the second quarter than they did a year ago, according to data from CB Insights. FierceBiotech ...

How Regeneron’s Yancopoulos became the top-paid executive in biotech

Ryan McBride Dr. George Yancopoulos is the highest paid biopharma executive in the world. In interviews with company leaders at Regeneron, FierceBiotech has learned more about why the ...

Will biotech investors cheer the impending round of IPOs?

Tracy Staton This batch has a combined money-raising goal of $ 350 million. Will investors cooperate with those hopes? FiercePharma News

$350M batch of biotech IPOs to test investors’ appetite for risk

John Carroll Just how much of an appetite is there for biotech IPOs? The industry may well find out over the next 8 days, with 6 new offerings slated to roll out. And 5 of them are ...

Agios Pharma sets terms for closely watched biotech IPO

Ryan McBride Agios Pharmaceuticals has advanced down the IPO pipeline. The Cambridge, MA-based biotech company has proposed a price range of $ 14 to $ 16 per share in an initial public ...

In hot biotech market, personalized drugs rise to the top

Ryan McBride Investor interest in biotech is enjoying a prosperous comeback, leading industry watchers and journalists to seek reasons for the frenzy. In The New York Times' ...

The biotech IPO scene turns red hot

John Carroll During all of last year there were only 11 biotech IPOs. But even that weak number looked pretty good compared to the barren years leading away from the 2008 financial ...

Cardio3 shares suffer as biotech fires back at criticism of PhII study

Ryan McBride Cardio3 BioSciences got an early taste of the downside being public this week. The Belgian biotech today undertook damage control after a Forbes blog report on Monday about ...

Swiss biotech OncoEthix snags $19M round to back leukemia drug study

John Carroll Switzerland's OncoEthix has raised $ 19 million in venture cash to back its work on an early-stage cancer treatment, one of a new class of oncology drugs that's ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS